Fierce Pharma
JULY 25, 2024
Three months after bagging FDA approval, Pfizer’s hemophilia B gene therapy has been cleared to expand its reach across the pond. | The company's first gene therapy will debut in Europe as Durveqtix. In the U.S., the drug is approved under the brand name Beqvez.
David Bagga
JULY 25, 2024
Medical Device Sales Academy How to Get Medical Device Sales Jobs with No Experience? Medical device sales become one of the best career options today. More and more people want to crack medical device sales jobs and earn a better living. However, things can seem challenging without prior experience in this field. You must wonder if you […] The post How to Get Medical Device Sales Jobs with No Experience?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JULY 25, 2024
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessmen | In a discussion prompted by AstraZeneca's application for Imfinzi, the FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer.
MedCity News
JULY 25, 2024
Autobahn Therapeutics’ platform technology enables small molecules to selectively hit targets in the brain. In addition to a lead program ready for Phase 2 testing in two types of depression, the startup has a preclinical molecule with potential applications in neuroinflammatory disorders such as multiple sclerosis. The post Fueled With $100M, Autobahn Therapeutics Gears Up for Depression Drug Clinical Trials appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
JULY 25, 2024
While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea fr | While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea.
MedCity News
JULY 25, 2024
A 10-year partnership between the two organization will standardize patient monitoring hardware and software across 49 Bon Secours Mercy Health hospitals. The post What Bon Secours’ 10-Year Partnership with Philips Hopes to Achieve appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
JULY 25, 2024
Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.
Fierce Pharma
JULY 25, 2024
Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine's global reach.
Pharmatutor
JULY 25, 2024
Extensive pharmacological review on Bauhinia racemosa Lam medicinal plant whose leaves are used to make Indian cigarettes (beedi’s) admin Fri, 07/26/2024 - 10:52 Devansh Mehta* M.Pharmacy in Pharmacology, M.B.A. in Pharmaceutical Marketing and Hospital Administration, Founding Medical Writing Director, TRM Writer’s LLP Modipuram, Meerut. *devanshm84@gmail.
Fierce Pharma
JULY 25, 2024
Among AstraZeneca’s growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo-partnered Enhertu to chart new territory. | Among AstraZeneca's growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo-partnered Enhertu to chart new territory. And stalling sales underscore the challenges facing the HER2 drug.
MedCity News
JULY 25, 2024
To bring cross-agency clinical leaders together, the FDA should establish a Center of Excellence for Rare Diseases. This would bring together specialized staff and resources from multiple review divisions to leverage their expertise about different bodily systems, trial designs, pharmacology, and other specialized fields. The post To Give Rare Disease Patients Hope, the FDA Must Re-Focus its Efforts appeared first on MedCity News.
Fierce Pharma
JULY 25, 2024
Following last week’s R&D day, argenx continues to demonstrate that its flagship drug, FcRn inhibitor Vyvgart, has plenty of room to grow in its inaugural generalized myasthenia gravis (gMG) in | Following last week’s R&D day, argenx continues to demonstrate that its flagship drug, FcRn inhibitor Vyvgart, has plenty of room to grow in its inaugural generalized myasthenia gravis (gMG) indication.
MedCity News
JULY 25, 2024
Headway’s $100 million Series D funding round was led by Spark Capital and included participation from Thrive Capital, Accel, a16z and Forerunner Ventures. The post Headway Secures $100M To Expand to MA/Medicaid Members appeared first on MedCity News.
Fierce Pharma
JULY 25, 2024
With a new chief at the helm and higher profit projections in sight, AbbVie is entering a “new chapter," CEO Robert Michael told analysts Thursday. | Skyrizi's recent ulcerative colitis nod sets it up as a first-line option, while Rinvoq is poised to handle later lines.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
MedCity News
JULY 25, 2024
The good news is that many ACOs have already made the transition to eCQM reporting. Proven best practices are now available. Savvy ACOs will capitalize on efforts to optimize broader quality initiatives under value-based payment over time. The post Electronic Quality Reporting Window Closing on MSSP ACOs: Time for Action Is Now appeared first on MedCity News.
Fierce Pharma
JULY 25, 2024
Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's antibody-drug conjugate star Enhertu experienced a slow quarter. | Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's ADC star Enhertu slowed down. Samsung Biologics' quarterly revenue crossed the 1 trillion Korean won mark for the first time.
Copyright Clearance Center
JULY 25, 2024
As AI continues to revolutionize corporate operations, a new collective licensing solution from CCC ensures that both content creators and users can thrive.
pharmaphorum
JULY 25, 2024
There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory with their experimental treatment.The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was better than regular prophylaxis injections with Factor VIII (FVIII) replacement therapies at reducing bleeding episodes, and could now be heading for regulatory review.
Pharmaceutical Technology
JULY 25, 2024
JNJ-2056 is being investigated in the Phase IIb ReTain study which enrols participants who are yet to show Alzheimer’s symptoms.
pharmaphorum
JULY 25, 2024
Tune in to the Reverba podcast featuring CEO Cheryl Lubbert as she discusses patient engagement throughout the product lifecycle, sharing insights and strategies for success.
PharmaTimes
JULY 25, 2024
Conditions such as Alzheimer’s and Parkinson’s affect over one million people in the UK
pharmaphorum
JULY 25, 2024
NICE clears NHS use of Boehringer's clot-busting drug Metalyse for acute ischaemic stroke, saying it could 'save millions'
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaTimes
JULY 25, 2024
The research will help to better understand how this pathway is coordinated in the cell
pharmaphorum
JULY 25, 2024
Digital dementia detection specialist Linus Health has expanded its patient care focus with the acquisition of Together Senior Health.
Pharmaceutical Commerce
JULY 25, 2024
The latest news for pharma industry insiders.
pharmaphorum
JULY 25, 2024
European pharma groups AstraZeneca, Sanofi, and Roche all raise their financial guidance for the year on stronger sales growth.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Contrarian Sales Techniques
JULY 25, 2024
I’ve been hearing a lot about Bank Negara Malaysia (BNM) talking about a co-payment policy for insurance. Honestly, it sounded like a mouthful at first. So, I did some digging to figure out what it means for us regular folks. What’s a Co-Payment Anyway? Think of it this way. When you go to the doctor, you usually pay a certain amount, right? That’s kind of like a co-payment.
pharmaphorum
JULY 25, 2024
FDA's ODAC doesn't vote on AstraZeneca's perioperative Imfinzi regimen in NSCLC but has deep reservations about the design of the phase 3 trial supporting it
Contrarian Sales Techniques
JULY 25, 2024
It might occur to you that a love story like "Love & Other Drugs" wouldn't have much to do with our daily grind. But actually, there's a surprising connection! The movie follows Jamie, a charming med rep who falls for Maggie, a woman with a chronic illness. As Jamie learns more about her condition, he starts to see his job in a whole new light. It's not just about selling pills, it's about the impact those meds have on people's lives.
PM360
JULY 25, 2024
Ian T. Clark brings over 35 years of pharmaceutical and healthcare expertise to GoodRx. GoodRx, the leading prescription savings platform in the U.S., today announced the election of Ian T. Clark to its Board of Directors. Mr. Clark brings to GoodRx over 35 years of experience in the pharmaceutical and healthcare industries. He formerly served as Chief Executive Officer of Genentech, a biotechnology company, and previously held leadership positions at Novartis, Sanofi, Ivax Pharmaceuticals and G
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
281 
Let's personalize your content